GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (FRA:260) » Definitions » Net Margin %

Centessa Pharmaceuticals (FRA:260) Net Margin % : -537.56% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Centessa Pharmaceuticals's Net Income for the three months ended in Dec. 2023 was €-33.78 Mil. Centessa Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was €6.28 Mil. Therefore, Centessa Pharmaceuticals's net margin for the quarter that ended in Dec. 2023 was -537.56%.

The historical rank and industry rank for Centessa Pharmaceuticals's Net Margin % or its related term are showing as below:

FRA:260' s Net Margin % Range Over the Past 10 Years
Min: -2204.66   Med: -2204.65   Max: -2204.65
Current: -2204.66


FRA:260's Net Margin % is ranked worse than
81.34% of 1029 companies
in the Biotechnology industry
Industry Median: -157.22 vs FRA:260: -2204.66

Centessa Pharmaceuticals Net Margin % Historical Data

The historical data trend for Centessa Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals Net Margin % Chart

Centessa Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
- - - - -2,204.73

Centessa Pharmaceuticals Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -537.56

Competitive Comparison of Centessa Pharmaceuticals's Net Margin %

For the Biotechnology subindustry, Centessa Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Centessa Pharmaceuticals's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Centessa Pharmaceuticals's Net Margin % falls into.



Centessa Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Centessa Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-138.545/6.284
=-2,204.73 %

Centessa Pharmaceuticals's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-33.78/6.284
=-537.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Centessa Pharmaceuticals  (FRA:260) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Centessa Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Centessa Pharmaceuticals (FRA:260) Business Description

Traded in Other Exchanges
Address
1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Centessa Pharmaceuticals (FRA:260) Headlines

No Headlines